Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
Immortalization of peripheral blood lymphocytes of cats by human T-cell leukemia virus.
Int J Cancer. 1984 Oct 15;34(4):513-7. Unique Identifier : AIDSLINE MED/85029462 Hoshino H; Tanaka H; Shimotohno K; Miwa M; Nagai M; Shimoyama M; Sugimura T
Abstract:
Peripheral blood lymphocytes of domestic cats were co-cultivated with lethally irradiated MT-2 cells, which produced human T-cell leukemia virus type 1 (HTLV-I). Two cat lymphoid cell lines, CaL-1 and CaL-2, established and maintained without exogenously added T-cell growth factor, were characterized after more than 6 months of cultivation. These cells grew in suspension, had a chromosome number of 38 and lacked cytoplasmic and surface immunoglobulins. CaL-2 cells formed E-rosettes. Both cell lines harbored HTLV genomes but not human Alu family sequences, which are highly repetitious in the human genome, suggesting that transfer of human DNA fragments was not necessary for their immortalization or transformation. HTLV antigens were detected in CaL-1 and CaL-2 cells by indirect immunofluorescence assay. CaL-1 and CaL-2 cells both expressed viral proteins with apparent molecular weights of 53 kd, 24 kd and 19 kd, and CaL-2 cells also expressed 28 kd and 20 kd proteins. Reverse transcriptase activity was detected in culture fluid of CaL-2 cells, but not of CaL-1 cells. CaL-2 cells but not CaL-1 cells had syncytium-induced activity. These findings indicated that lymphocytes of cats, especially T lymphocytes, were susceptible to infection with HTLV and to immortalization by HTLV.
Keywords: Animal Antibodies, Monoclonal/ANALYSIS Antigens, Viral/ANALYSIS Cats Cell Line DNA/GENETICS DNA, Viral/GENETICS Genes, Viral Human HTLV-BLV Viruses/GENETICS/IMMUNOLOGY/*ISOLATION & PURIF Immunologic Techniques Lymphocytes/IMMUNOLOGY/*MICROBIOLOGY Male Nucleic Acid Hybridization Support, Non-U.S. Gov't Virus Cultivation/METHODS JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
